Alpha Cognition Inc (ACOG) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alpha Cognition Inc stock (ACOG) is currently trading at $5.59. Alpha Cognition Inc PS ratio (Price-to-Sales) is 16.72. Analyst consensus price target for ACOG is $18.00. WallStSmart rates ACOG as Sell.
- ACOG PE ratio analysis and historical PE chart
- ACOG PS ratio (Price-to-Sales) history and trend
- ACOG intrinsic value — DCF, Graham Number, EPV models
- ACOG stock price prediction 2025 2026 2027 2028 2029 2030
- ACOG fair value vs current price
- ACOG insider transactions and insider buying
- Is ACOG undervalued or overvalued?
- Alpha Cognition Inc financial analysis — revenue, earnings, cash flow
- ACOG Piotroski F-Score and Altman Z-Score
- ACOG analyst price target and Smart Rating
Alpha Cognition Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Alpha Cognition Inc (ACOG) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Alpha Cognition Inc (ACOG) Key Strengths (1)
52.78% held by institutions, strong professional interest
Supporting Valuation Data
Alpha Cognition Inc (ACOG) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 16.7x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.7x book value
Supporting Valuation Data
Alpha Cognition Inc (ACOG) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (16.72), Price/Book (3.67) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -125.60%, Operating Margin at -187.00%, Profit Margin at -262.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -125.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACOG Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ACOG's Price-to-Sales ratio of 16.72x sits near its historical average of 16.99x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 5% below its historical high of 17.56x set in Mar 2026, and 0% above its historical low of 16.72x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Alpha Cognition Inc (ACOG) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Alpha Cognition Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 7M with 0% growth year-over-year. The company is currently unprofitable, posting a -262.2% profit margin.
Key Findings
The company is unprofitable with a -262.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.55, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Alpha Cognition Inc.
Bottom Line
Alpha Cognition Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:21:52 AM
About Alpha Cognition Inc(ACOG)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Alpha Cognition Inc. is a pioneering biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, is designed to enhance cognitive function in patients and address significant unmet medical needs within the aging population. Driven by a robust R&D strategy and a proprietary neuroscience platform, Alpha Cognition is strategically positioned to revolutionize patient care in this critical area. As the company continues to advance its clinical pipeline and explore new therapeutic avenues, it represents a compelling opportunity for institutional investors navigating the evolving healthcare landscape.